Trials / Unknown
UnknownNCT00434369
5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients
A Multi-Center, Open-Label, Single-Arm Phase II Trial Assessing the Efficacy and Safety of Weekly Bolus Infusions of 5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Advanced Breast Cancer Patients Who Failed Anthracycline and Taxane Chemotherapy Regimens
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Mast Therapeutics, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multi-center, open-label, single-arm Phase II trial assessing the efficacy and safety of weekly bolus infusions of 5-fluorouracil combined with CoFactor (5-10 methylenetetrahydrofolate) in advanced breast cancer patients who failed anthracycline and taxane chemotherapy regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CoFactor (ANX-510) |
Timeline
- Start date
- 2006-02-01
- First posted
- 2007-02-13
- Last updated
- 2008-04-22
Locations
6 sites across 5 countries: Argentina, Mexico, Peru, Russia, Spain
Source: ClinicalTrials.gov record NCT00434369. Inclusion in this directory is not an endorsement.